Loading...

Peisheng Hu, PhD

Title(s)Research Assistant Professor of Pathology (Part-Time)
AddressHMR 201, 2011 Zonal Ave
Health Sciences Campus
Los Angeles CA 90089-9092
Phone+1 323 442 1622
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations. Antibodies (Basel). 2020 Jun 10; 9(2). Boune S, Hu P, Epstein AL, Khawli LA. PMID: 32532067.
      View in: PubMed   Mentions:
    2. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models. Clin Cancer Res. 2020 Apr 09. Zheng L, Ren L, Kouhi A, Khawli LA, Hu P, Kaslow HR, Epstein AL. PMID: 32273277.
      View in: PubMed   Mentions:    Fields:    
    3. Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetes. Nat Commun. 2019 02 12; 10(1):713. Galle-Treger L, Sankaranarayanan I, Hurrell BP, Howard E, Lo R, Maazi H, Lewis G, Banie H, Epstein AL, Hu P, Rehan VK, Gilliland FD, Allayee H, Soroosh P, Sharpe AH, Akbari O. PMID: 30755607.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    4. Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. Int J Mol Sci. 2017 Dec 20; 18(12). Zheng L, Hu P, Wolfe B, Gonsalves C, Ren L, Khawli LA, Kaslow HR, Epstein AL. PMID: 29261129.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    5. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein AL. PMID: 26960932.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    6. Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia®) in Dogs with Spontaneous Malignancies. J Cancer Sci Ther. 2015; 7(6):167-174. Jang JK, Chretin J, Bruyette D, Hu P, Epstein AL. PMID: 26635918.
      View in: PubMed   Mentions:
    7. A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano. 2014 Mar 25; 8(3):2064-76. Aluri SR, Shi P, Gustafson JA, Wang W, Lin YA, Cui H, Liu S, Conti PS, Li Z, Hu P, Epstein AL, MacKay JA. PMID: 24484356.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    8. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. PMID: 24145359.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    9. Generation of tumor-targeted antibody-CpG conjugates. J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. Li Z, Jang JK, Lechner MG, Hu P, Khawli L, Scannell CA, Epstein AL. PMID: 23279945.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    10. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 2008 Apr; 31(3):235-45. Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL. PMID: 18317364.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    11. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008 Jan 15; 14(2):579-88. Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein AL. PMID: 18223234.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    12. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007 Jul 01; 13(13):4016-25. Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, Epstein AL. PMID: 17606736.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    13. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. Zhang N, Khawli LA, Hu P, Epstein AL. PMID: 17651040.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    14. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. Arias RS, Flanagan ML, Miller KD, Nien YC, Hu P, Gray D, Khawli LA, Epstein AL. PMID: 17600493.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    15. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007 May 01; 13(9):2758-67. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL. PMID: 17460060.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    16. Soluble Fc fusion proteins for biomedical research. Methods Mol Biol. 2007; 378:33-52. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL. PMID: 18605076.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCellsPHPublic Health
    17. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. Liu A, Hu P, Khawli LA, Epstein AL. PMID: 16799338.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    18. H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother. 2006 May-Jun; 29(3):274-83. Flanagan ML, Khawli LA, Hu P, Epstein AL. PMID: 16699370.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    19. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. Liu A, Hu P, Khawli LA, Epstein AL. PMID: 16322313.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    20. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. Zhang N, Khawli LA, Hu P, Epstein AL. PMID: 16115941.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    21. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. Khawli LA, Hu P, Epstein AL. PMID: 15837764.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    22. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics. 2004 Feb; 23(1):1-10. Li J, Hu P, Khawli LA, Yun A, Epstein AL. PMID: 15000842.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    23. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res. 2003 Dec 01; 63(23):8384-92. Li J, Hu P, Khawli LA, Epstein AL. PMID: 14679000.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    24. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. Khawli LA, Alauddin MM, Hu P, Epstein AL. PMID: 14969605.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    25. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003 Aug 15; 63(16):5046-53. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. PMID: 12941833.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    26. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics. 2003 Aug; 22(4):197-207. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL. PMID: 14511565.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    27. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother. 2003 Jul-Aug; 26(4):320-31. Li J, Hu P, Khawli LA, Epstein AL. PMID: 12843794.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    28. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. Biela BH, Khawli LA, Hu P, Epstein AL. PMID: 12954121.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    29. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003 May 21; 95(10):741-9. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. PMID: 12759392.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    30. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003 Jun 15; 101(12):4853-61. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. PMID: 12609842.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    31. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics. 2003 Feb; 22(1):1-9. Khawli LA, Biela B, Hu P, Epstein AL. PMID: 12713684.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    32. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics. 2002 Dec; 21(6):421-32. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. PMID: 12573106.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    33. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm. 2002 Aug; 17(4):359-70. Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. PMID: 12396700.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    34. Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. Hybrid Hybridomics. 2002 Feb; 21(1):11-8. Khawli LA, Biela BH, Hu P, Epstein AL. PMID: 11991812.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    Peisheng's Networks
    Concepts (204)
    Derived automatically from this person's publications.
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _